The NEPTUNE study has shown brepocitinib to significantly lower Treatment Failure rates in NIU patients. Can you elaborate on the importance of these findings and how they compare to the current standard of care?

Brepocitinib is noted for its dual TYK2/JAK1 inhibition. How does this mechanism of action contribute to its efficacy in treating NIU, and what does this suggest about the role of these pathways in autoimmune ocular diseases?

Given the over 1,400 subjects treated with brepocitinib across various studies, how does its safety profile stand out, especially in comparison to other treatments for NIU and related autoimmune diseases?

The resolution of uveitic macular edema in a significant portion of patients treated with brepocitinib is noteworthy. How does this outcome affect the overall prognosis and quality of life for patients with NIU?

Roivant Sciences has announced a substantial share repurchase program, including the repurchase of the Sumitomo Pharma stake. What implications might these financial strategies have for Roivant's operational freedom and future investment in R&D?

With the anticipated initiation of a Phase 3 program for NIU, what are the key considerations and endpoints that researchers should focus on to ensure the continued success of brepocitinib?

Considering brepocitinib's promising results in NIU and its ongoing study in dermatomyositis, what potential does this drug have in transforming the treatment landscape for specialty autoimmunity diseases?

Non-infectious uveitis can lead to severe visual impairment or blindness. From a patient-centric viewpoint, how could brepocitinib's once-daily oral administration change the treatment paradigm and patient adherence in NIU therapy?